Math­ai Mam­men hands in J&J's R&D keys to lead Greg Ver­dine’s Fog­Phar­ma 

In the ear­ly 1990s, Math­ai Mam­men was a teach­ing as­sis­tant in Greg Ver­dine’s Sci­ence B46 course at Har­vard. In June, the for­mer R&D head at John­son & John­son will suc­ceed Ver­dine as CEO, pres­i­dent and chair of Fog­Phar­ma, the same month the sev­en-year-old biotech kick­starts its first clin­i­cal tri­al.

Af­ter lead­ing R&D at one of the largest drug­mak­ers in the world, tak­ing the com­pa­ny through more than half a dozen drug ap­provals in the past few years, not to men­tion a Covid-19 vac­cine race, Mam­men de­part­ed J&J last month and will take the helm of a Cam­bridge, MA biotech at­tempt­ing to go af­ter what Ver­dine calls the “true em­per­or of all onco­genes” — be­ta-catenin.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN